Alvotech Expands its Collaboration with Fuji Pharma to Add a New Biosimilar Candidate
Shots:
- The collaboration expanded to add a new biosimilar candidate & increase patient access to vital biologic medicines in Japan. In Oct 2022, the companies have submitted an application to MHLW for marketing approval of the first biosimilar candidate
- The agreement which covers 7 biosimilars, incl. the new candidate, to be developed & manufactured by Alvotech & commercialized by Fuji in Japan, was first announced by Alvotech & Fuji in Nov 2018. It was previously extended in Dec 2020 & Feb 2022
- Fuji Pharma’s main focus is on the development & commercialization of hormone medicines for obstetrics & gynecology therapies, injectable drugs incl. diagnostic pharmaceutical products
Ref: Globenewswire | Image: Alvotech
Related News:- Alvotech’s Partner Fuji Pharma Report Submission of Application to MHLW for Approval of First Biosimilar Candidate in Japan
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
